迷走神經刺激治療藥物難治性癲癇的中國專家共識_Journal of Epilepsy

Authors：

 中國抗癲癇協會神經調控專業委員會 ,  中國醫師協會神經調控專業委員會 ,  中華醫學會神經外科分會神經生理學組

執筆（排名不分先后）吳曄（北京大學第一醫院），周健（首都醫科大學三博腦科醫院），關宇光（首都醫科大學三博腦科醫院），孟凡剛（北京市神經外科研究所、首都醫科大學附屬天壇醫院），季濤云（北京大學第一醫院）;

Corresponding?author：

中國抗癲癇協會神經調控專業委員會, Email: luangm3@163.com; 中國醫師協會神經調控專業委員會, Email: jiangyuwu@bjmu.edu.cn; 中華醫學會神經外科分會神經生理學組, Email: zjguo73@126.com

Keywords：

DOI：

10.7507/2096-0247.20210031

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 中國抗癲癇協會神經調控專業委員會, 中國醫師協會神經調控專業委員會, 中華醫學會神經外科分會神經生理學組. 迷走神經刺激治療藥物難治性癲癇的中國專家共識. Journal of Epilepsy, 2021, 7(3): 191-196. doi: 10.7507/2096-0247.20210031 Copy

1.	中華醫學會編著臨床診療指南·癲癇病分冊(2015修訂版). 北京: 人民衛生出版社, 2015.6.
2.	Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51(6): 1069-77.
3.	Famm K, Litt B, Tracey KJ, et al. Drug discovery: a jump-start for electroceuticals. Nature, 2013, 496(7444): 159-161.
4.	Smalley E. The business of brain-computer interfaces. Nat Biotechnol, 2019, 37(9): 978-982.
5.	Hachem LD, Wong SM, Ibrahim GM. The vagus afferent network: emerging role in translational connectomics. Neurosurg Focus, 2018, 45(3): E2.
6.	Johnson RL, Wilson CG. A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res, 2018, 11: 203-213.
7.	Spencer SS. Neural networks in human epilepsy: evidence of and implications for treatment. Epilepsia, 2002, 43(3): 219-227.
8.	Engineer ND, Riley JR, Seale JD, et al. Reversing pathological neural activity using targeted plasticity. Nature, 2011, 470(7332): 101-104.
9.	Cai PY, Bodhit A, Derequito, et al. Vagus nerve stimulation in ischemic stroke: old wine in a new bottle. Front Neurol, 2014, 5: 107.
10.	張建國, 張凱, 孟凡剛主編. 迷走神經刺激術, 北京: 人民衛生出版社, 2019, ISBN 978-7-117-28935-1.
11.	孟凡剛, 張凱, 邵曉秋, 等. 國產迷走神經刺激器治療藥物難治性癲癇的前瞻性多中心隨機對照臨床試驗研究. 中華神經外科雜志, 2016, 32(9): 913-917.
12.	中國醫師協會神經內科分會癲專委會. 迷走神經刺激術治療癲(癎)的中國專家共識. 中國醫師雜志, 2015, 17(7): 967-968.
13.	Muthiah N, Zhang J, Remick M, et al. Efficacy of vagus nerve stimulation for drug-resistant epilepsy in children age six and younger. Epilepsy Behav, 2020, 112: 107373.
14.	Orosz I, McCormick D, Zamponi N, et al. Vagus nerve stimulation for drug-resistant epilepsy: A European long-term study up to 24 months in 347 children. Epilepsia, 2014, 55(10): 1576-1584.
15.	Liu H, Yang Z, Huang L, et al. Heart-rate variability indices as predictors of the response to vagus nerve stimulation in patients with drug-resistant epilepsy. Epilepsia, 2017, 58(6): 1015-1022.
16.	Liu HY, Yang Z, Meng FG, et al. Preoperative Heart Rate Variability as Predictors of Vagus Nerve Stimulation Outcome in Patients with Drug-resistant Epilepsy. Sci Rep, 2018, 8(1): 3856.
17.	Mithani K, Mikhail M, Morgan BR, et al. Connectomic Profiling Identifies Responders to Vagus Nerve Stimulation. Ann Neurol, 2019, 86(5): 743-753.
18.	Workewych AM, Arski ON, Mithani K, et al. Biomarkers of seizure response to vagus nerve stimulation: A scopingreview. Epilepsia, 2020, 61(10): 2069-2085.
19.	李超, 馬翔宇, 徐碩, 等. 頸部單切口在迷走神經刺激術中的應用. 中華神經外科雜志, 2017, 33(6): 640-641.
20.	Xie H, Ji T, Ma J, et al. Remote programming: A convenient and cost-effective measure of vagus nerve stimulation for children with epilepsy. Epilepsy Res, 2020, 159: 106246.
21.	Eggleston KS, Olin BD, Fisher RS. Ictal tachycardia: the head-heart connection. Seizure, 2014, 23(7): 496-505.
22.	姜玉武. 兒童癲癇治療需重視頂層設計和適時合理使用多種治療方法. 中華兒科雜志, 2020, 58(11): 867-870.
23.	González HFJ, Yengo-Kahn A, Englot DJ. Vagus Nerve Stimulation for the Treatment of Epilepsy. Neurosurg Clin N Am, 2019, 30(2): 219-230.
24.	Morris GL 3rd, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2013, 81(16): 1453-1459.
25.	Chrastina J, Novák Z, Zeman T, et al. Single-center long-term results of vagus nerve stimulation for epilepsy: A 10-17 year follow-up study. Seizure, 2018, 59: 41-47.
26.	Kuba R, Brázdil M, Kalina M, et al. Vagus nerve stimulation: longitudinal follow-up of patients treated for 5 years. Seizure, 2009, 18(4): 269-274.
27.	Wang HJ, Tan G, Zhu LN, et al. Predictors of seizure reduction outcome after vagus nerve stimulation in drug-resistant epilepsy. Seizure, 2019, 66: 53-60.
28.	Kossoff EH, Shields WD. Nonpharmacologic care for patients with Lennox-Gastaut syndrome: ketogenic diets and vagus nerve stimulation. Epilepsia, 2014, 55(Suppl 4): 29-33.
29.	Dibué-Adjei M, Fischer I, Steiger HJ, et al. Efficacy of adjunctive vagus nerve stimulation in patients with Dravet syndrome: A meta-analysis of 68 patients. Seizure, 2017, 50: 147-152.
30.	Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg, 2011, 115(6): 1248-1255.
31.	Fan PC, Peng SSF, Yen RF, et al. Neuroimaging and electroencephalographic changes after vagus nerve stimulation in a boy with medically intractable myoclonic astatic epilepsy. J Formos Med Assoc, 2014, 113(4): 258-263.
32.	Wilfong AA, Schultz RJ. Vagus nerve stimulation for treatment of epilepsy in Rett syndrome. Dev Med Child Neurol, 2006, 48(8): 683-686.
33.	Welch WP, Sitwat B, Sogawa Y. Use of Vagus Nerve Stimulator on children with primary generalized epilepsy. J Child Neurol, 2018, 33(7): 449-452.
34.	Dibué-Adjei M, Brigo F, Yamamoto T. Vagus nerve stimulation in refractory and super-refractory status epilepticus - A systematic review. Brain Stimul, 2019, 12(5): 1101-1110.
35.	Toffa DH, Touma L, El Meskine T, et al. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: A critical review. Seizure, 2020, 83: 104-123.
36.	Wheless JW, Gienapp AJ, Ryvlin P. Vagus nerve stimulation (VNS) therapy update. Epilepsy Behav, 2018, 88(Suppl): 2-10.
37.	Spindler P, Bohlmann K, Straub HB, et al. Effects of vagus nerve stimulation on symptoms of depression in patients with difficult-to-treat epilepsy. Seizure, 2019, 69: 77-79.
38.	Annegers JF, Coan SP, Hauser WA, et al. Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. Epilepsia, 2000, 41(5): 549-553.
39.	Englot DJ, Hassnain KH, Rolston JD, et al. Quality-of-life metrics with vagus nerve stimulation for epilepsy from provider survey data. Epilepsy Behav, 2017, 66: 4-9.
40.	Levy ML, Levy KM, Hoff D, et al. Vagus nerve stimulation therapy in patients with autism spectrum disorder and intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry. J NeurosurgPediatr, 2010, 5(6): 595-602.
41.	Elliott RE, Morsi A, Kalhorn SP, et al. Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsy Behav, 2011, 20(1): 57-63.
42.	Révész D, Rydenhag B, Ben-Menachem E. Complications and safety of vagus nerve stimulation: 25 years of experience at a single center. J NeurosurgPediatr, 2016, 18(1): 97-104.
43.	Ohemeng KK, Parham K. Vagal nerve stimulation: indications, implantation, and outcomes. Otolaryngol Clin North Am, 2020, 53(1): 127-143.
44.	Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology, 1998, 51(1): 48-55.
45.	Liporace J, Hucko D, Morrow R, et al. Vagal nerve stimulation: adjustments to reduce painful side effects. Neurology, 2001, 57(5): 885-886.
46.	Frei MG, Osorio I. Left vagus nerve stimulation with the neurocybernetic prosthesis has complex effects on heart rate and on its variability in humans. Epilepsia, 2001, 42(8): 1007-1116.
47.	Binks AP, Paydarfar D, Schachter SC, et al. High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects. Respir Physiol, 2001, 127(2-3): 125-133.

1. 中華醫學會編著臨床診療指南·癲癇病分冊(2015修訂版). 北京: 人民衛生出版社, 2015.6.
2. Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia, 2010, 51(6): 1069-77.
3. Famm K, Litt B, Tracey KJ, et al. Drug discovery: a jump-start for electroceuticals. Nature, 2013, 496(7444): 159-161.
4. Smalley E. The business of brain-computer interfaces. Nat Biotechnol, 2019, 37(9): 978-982.
5. Hachem LD, Wong SM, Ibrahim GM. The vagus afferent network: emerging role in translational connectomics. Neurosurg Focus, 2018, 45(3): E2.
6. Johnson RL, Wilson CG. A review of vagus nerve stimulation as a therapeutic intervention. J Inflamm Res, 2018, 11: 203-213.
7. Spencer SS. Neural networks in human epilepsy: evidence of and implications for treatment. Epilepsia, 2002, 43(3): 219-227.
8. Engineer ND, Riley JR, Seale JD, et al. Reversing pathological neural activity using targeted plasticity. Nature, 2011, 470(7332): 101-104.
9. Cai PY, Bodhit A, Derequito, et al. Vagus nerve stimulation in ischemic stroke: old wine in a new bottle. Front Neurol, 2014, 5: 107.
10. 張建國, 張凱, 孟凡剛主編. 迷走神經刺激術, 北京: 人民衛生出版社, 2019, ISBN 978-7-117-28935-1.
11. 孟凡剛, 張凱, 邵曉秋, 等. 國產迷走神經刺激器治療藥物難治性癲癇的前瞻性多中心隨機對照臨床試驗研究. 中華神經外科雜志, 2016, 32(9): 913-917.
12. 中國醫師協會神經內科分會癲專委會. 迷走神經刺激術治療癲(癎)的中國專家共識. 中國醫師雜志, 2015, 17(7): 967-968.
13. Muthiah N, Zhang J, Remick M, et al. Efficacy of vagus nerve stimulation for drug-resistant epilepsy in children age six and younger. Epilepsy Behav, 2020, 112: 107373.
14. Orosz I, McCormick D, Zamponi N, et al. Vagus nerve stimulation for drug-resistant epilepsy: A European long-term study up to 24 months in 347 children. Epilepsia, 2014, 55(10): 1576-1584.
15. Liu H, Yang Z, Huang L, et al. Heart-rate variability indices as predictors of the response to vagus nerve stimulation in patients with drug-resistant epilepsy. Epilepsia, 2017, 58(6): 1015-1022.
16. Liu HY, Yang Z, Meng FG, et al. Preoperative Heart Rate Variability as Predictors of Vagus Nerve Stimulation Outcome in Patients with Drug-resistant Epilepsy. Sci Rep, 2018, 8(1): 3856.
17. Mithani K, Mikhail M, Morgan BR, et al. Connectomic Profiling Identifies Responders to Vagus Nerve Stimulation. Ann Neurol, 2019, 86(5): 743-753.
18. Workewych AM, Arski ON, Mithani K, et al. Biomarkers of seizure response to vagus nerve stimulation: A scopingreview. Epilepsia, 2020, 61(10): 2069-2085.
19. 李超, 馬翔宇, 徐碩, 等. 頸部單切口在迷走神經刺激術中的應用. 中華神經外科雜志, 2017, 33(6): 640-641.
20. Xie H, Ji T, Ma J, et al. Remote programming: A convenient and cost-effective measure of vagus nerve stimulation for children with epilepsy. Epilepsy Res, 2020, 159: 106246.
21. Eggleston KS, Olin BD, Fisher RS. Ictal tachycardia: the head-heart connection. Seizure, 2014, 23(7): 496-505.
22. 姜玉武. 兒童癲癇治療需重視頂層設計和適時合理使用多種治療方法. 中華兒科雜志, 2020, 58(11): 867-870.
23. González HFJ, Yengo-Kahn A, Englot DJ. Vagus Nerve Stimulation for the Treatment of Epilepsy. Neurosurg Clin N Am, 2019, 30(2): 219-230.
24. Morris GL 3rd, Gloss D, Buchhalter J, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology, 2013, 81(16): 1453-1459.
25. Chrastina J, Novák Z, Zeman T, et al. Single-center long-term results of vagus nerve stimulation for epilepsy: A 10-17 year follow-up study. Seizure, 2018, 59: 41-47.
26. Kuba R, Brázdil M, Kalina M, et al. Vagus nerve stimulation: longitudinal follow-up of patients treated for 5 years. Seizure, 2009, 18(4): 269-274.
27. Wang HJ, Tan G, Zhu LN, et al. Predictors of seizure reduction outcome after vagus nerve stimulation in drug-resistant epilepsy. Seizure, 2019, 66: 53-60.
28. Kossoff EH, Shields WD. Nonpharmacologic care for patients with Lennox-Gastaut syndrome: ketogenic diets and vagus nerve stimulation. Epilepsia, 2014, 55(Suppl 4): 29-33.
29. Dibué-Adjei M, Fischer I, Steiger HJ, et al. Efficacy of adjunctive vagus nerve stimulation in patients with Dravet syndrome: A meta-analysis of 68 patients. Seizure, 2017, 50: 147-152.
30. Englot DJ, Chang EF, Auguste KI. Vagus nerve stimulation for epilepsy: a meta-analysis of efficacy and predictors of response. J Neurosurg, 2011, 115(6): 1248-1255.
31. Fan PC, Peng SSF, Yen RF, et al. Neuroimaging and electroencephalographic changes after vagus nerve stimulation in a boy with medically intractable myoclonic astatic epilepsy. J Formos Med Assoc, 2014, 113(4): 258-263.
32. Wilfong AA, Schultz RJ. Vagus nerve stimulation for treatment of epilepsy in Rett syndrome. Dev Med Child Neurol, 2006, 48(8): 683-686.
33. Welch WP, Sitwat B, Sogawa Y. Use of Vagus Nerve Stimulator on children with primary generalized epilepsy. J Child Neurol, 2018, 33(7): 449-452.
34. Dibué-Adjei M, Brigo F, Yamamoto T. Vagus nerve stimulation in refractory and super-refractory status epilepticus - A systematic review. Brain Stimul, 2019, 12(5): 1101-1110.
35. Toffa DH, Touma L, El Meskine T, et al. Learnings from 30 years of reported efficacy and safety of vagus nerve stimulation (VNS) for epilepsy treatment: A critical review. Seizure, 2020, 83: 104-123.
36. Wheless JW, Gienapp AJ, Ryvlin P. Vagus nerve stimulation (VNS) therapy update. Epilepsy Behav, 2018, 88(Suppl): 2-10.
37. Spindler P, Bohlmann K, Straub HB, et al. Effects of vagus nerve stimulation on symptoms of depression in patients with difficult-to-treat epilepsy. Seizure, 2019, 69: 77-79.
38. Annegers JF, Coan SP, Hauser WA, et al. Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. Epilepsia, 2000, 41(5): 549-553.
39. Englot DJ, Hassnain KH, Rolston JD, et al. Quality-of-life metrics with vagus nerve stimulation for epilepsy from provider survey data. Epilepsy Behav, 2017, 66: 4-9.
40. Levy ML, Levy KM, Hoff D, et al. Vagus nerve stimulation therapy in patients with autism spectrum disorder and intractable epilepsy: results from the vagus nerve stimulation therapy patient outcome registry. J NeurosurgPediatr, 2010, 5(6): 595-602.
41. Elliott RE, Morsi A, Kalhorn SP, et al. Vagus nerve stimulation in 436 consecutive patients with treatment-resistant epilepsy: long-term outcomes and predictors of response. Epilepsy Behav, 2011, 20(1): 57-63.
42. Révész D, Rydenhag B, Ben-Menachem E. Complications and safety of vagus nerve stimulation: 25 years of experience at a single center. J NeurosurgPediatr, 2016, 18(1): 97-104.
43. Ohemeng KK, Parham K. Vagal nerve stimulation: indications, implantation, and outcomes. Otolaryngol Clin North Am, 2020, 53(1): 127-143.
44. Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology, 1998, 51(1): 48-55.
45. Liporace J, Hucko D, Morrow R, et al. Vagal nerve stimulation: adjustments to reduce painful side effects. Neurology, 2001, 57(5): 885-886.
46. Frei MG, Osorio I. Left vagus nerve stimulation with the neurocybernetic prosthesis has complex effects on heart rate and on its variability in humans. Epilepsia, 2001, 42(8): 1007-1116.
47. Binks AP, Paydarfar D, Schachter SC, et al. High strength stimulation of the vagus nerve in awake humans: a lack of cardiorespiratory effects. Respir Physiol, 2001, 127(2-3): 125-133.

Next Article
A Meta-analysis of effectiveness and safety of steroids combined with antiepileptic drugs in the treatment of children with epileptic electrical status during sleep

Journal of Epilepsy

迷走神經刺激治療藥物難治性癲癇的中國專家共識

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content